LUTETIUM (LU177) LILOTOMAB SATETRAXETAN
UNII 054ZP16K2Q

Substance Identification & Data

This profile provides standardized clinical and technical data for Lutetium (lu177) Lilotomab Satetraxetan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 054ZP16K2Q.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1453362-90-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

054ZP16K2Q

CAS Registry Number

1453362-90-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LUTETIUM (LU177) LILOTOMAB SATETRAXETAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C162565

National Cancer Institute reference terminology for clinical and research data.

INN ID

10078

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-252

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Lutetium (lu177) Lilotomab Satetraxetan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LUTETIUM (177LU) LILOTOMAB SATETRAXETAN

LUTETIUM (LU177) LILOTOMAB SATETRAXETAN

Common Names & Synonyms

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37 (TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY, LUTETIUM (LU 177) RADIOLABELLED SATETRAXETAN (DOTA DERIVATIVE) CONJUGATE

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD37 (TSPAN26, TETRASPANIN-26)), MUS MUSCULUS MONOCLONAL ANTIBODY, LUTETIUM (LU 177) RADIOLABELLED SATETRAXETAN (DOTA DERIVATIVE) CONJUGATE; GAMMA1 HEAVY CHAIN (1-443) (MUS MUSCULUS VH (IGHV1S135*01 (96.90%)-(IGHD)-IGHJ4*01) (8.8.12) (1-119)-IGHG1*01 (CH1 E84>Q (177), P95>T (193), R96>W (194) (120-216), HINGE (217-229), CH2 (230-336), CH3 N84.2>D (395), N84.4>D (397) (337-441), CHS (442-443)) (120-443)), (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (MUS MUSCULUS V-KAPPA (IGKV6-25*01 (93.70%)-IGKJ4*01) (6.3.9) (1'-107')-IGKC*01 (108'-214')); DIMER (223-223'':226-226'':228-228'')-TRISDISULFIDE, AN AVERAGE OF 1 TO 2 AMINO GROUPS (N6 OF LYSINES) ARE SUBSTITUTED: N-(RAC-(4-(((2R)-1,4,7,10-TETRAKIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODECAN-2-YL)METHYL)PHENYL)CARBAMOTHIOYL) ( 177LU)LUTETIUM(3+) CHELATE

LILOTOMAB SATETRAXETAN LUTETIUM LU-177

LUTETIUM (177LU) LILOTOMAB SATETRAXETAN [INN]

LUTETIUM (177LU) LILOTOMAB SATETRAXETAN [WHO-DD]

LUTETIUM (LU177) LILOTOMAB SATETRAXETAN [USAN]